Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's
Biotech
Biogen axes asset from $7.3B buyout, plus Alzehimer’s prospect
Biogen is axing a phase 2 program acquired in the $7.3 billion Reata buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects into touch.
Nick Paul Taylor
Feb 12, 2025 9:53am
GSK pays Muna $35M cash to chase new Alzheimer's drug targets
Dec 5, 2024 7:00am
Alector lays off 17% of staff after ph. 2 Alzheimer's drug fail
Nov 26, 2024 4:50am
Advantage spins out anti-aging R&D to new biotech Klothea
Nov 25, 2024 11:56am
Patient death prompts Roche to adjust Alzheimer's trial
Oct 30, 2024 11:40am
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
